bosentan anhydrous has been researched along with Peripheral Arterial Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fontaine, C; Jaquinandi, V; Mahe, G; Omarjee, L | 1 |
| Acin, F; Bleda, S; De Haro, J; Gonzalez-Hidalgo, C; Michel, I | 1 |
1 trial(s) available for bosentan anhydrous and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Long-Term Effects of Bosentan on Cardiovascular Events in Hispanic Patients with Intermittent Claudication: Four-Year Follow-up of the CLAU Trial : The CLAU Randomized Trial Long-Term Outcome.
Topics: Antihypertensive Agents; Atherosclerosis; Bosentan; Follow-Up Studies; Hispanic or Latino; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Arterial Disease; Treatment Outcome | 2019 |
1 other study(ies) available for bosentan anhydrous and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis: A case report.
Topics: Bosentan; Cardiovascular Agents; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Middle Aged; Peripheral Arterial Disease; Phosphodiesterase 5 Inhibitors; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides | 2017 |